The companies will develop a portfolio of indexed adapters specifically designed for multiplex NGS and optimized for use on Illumina systems such as the NovaSeq.
The agreement provides researchers with local customer care, and allows them to order reagents from within the country rather than importing them.
The technology has been a core capability of the firm, which is expanding its suite of products to address the broader needs of genomics researchers.
The acquisition of GeneWorks' oligo business widens IDT's reach in the Asia-Pacific region, the company said.
IDT has licensed the CRISPR/Cpf1 RNA-guided editing system from the Broad Institute and intends to sell it to pharmaceutical and other commercial labs.
The Hereditary Cancer Solution combines target capture probes from Integrated DNA Technologies with specialized analytics developed by Sophia.
The acquisition of San Diego-based ValueGene expands IDT's presence in Southern California.
The companies will combine their respective technologies and expertise to develop new products for low-input, targeted RNA-seq applications.
As the interference proceeding to resolve claims in foundational CRISPR patents draws near, Caribou has given IDT worldwide rights to sell RUO reagents.
The partnership will pair Sophia's informatics infrastructure with IDT's panel to provide an NGS-based solution for routine clinical diagnostics.
Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.
US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.
A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.
In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.